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conclusion, haploidentical HSCT with post-transplant cyclo-
phosphamide is a feasible alternative for X-ALD lacking a
suitable matched donor. Graft failure is still an obstacle that
has to be better prevented.245
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The standard of care for the transplantation of pediatric pa-
tients with acute leukemia and prior CNS disease is the use of
total body irradiation (TBI), plus a CNS radiation therapy (RT)
boost. However, the late effects of radiation can be pro-
hibitive, especially in younger children or those who have
previously received radiation therapy. We developed a
chemotherapy-only cytoreductive regimenwith the intent of
targeting the CNS with agents that can readily cross the
blood brain barrier and achieve high concentrations. We
used the combination of Busulfan (1mg/kg every 6 hours x 3
days), melphalan (50mg/m2/day x 2 days), and thiotepa IV
(8.3mg/kg/day or 250mg/m2/day x 2 days).
We treated six patients with acute myelogenous leukemia
(AML (N¼5) or acute lymphoblastic leukemia (ALL) with this
regimen from July 1999 and February 2013. The median age
at the time of HSCT was 2.8 years (range 1.7 to 13.4 years).
Patients were in complete CNS remission (CR) CR1 (N¼1),
CR2 (N¼3), CR3 (N¼1), and CR8 (N¼1). All six patients were
treated with multiple intrathecal chemotherapy agents prior
to transplant. Four of six patients received cranio-spinal
radiation therapy (RT) prior to HSCT; RT was required to
achieve a CNS CR in 3 of 4 of these patients. One patient
received CNS RT post HSCT, while one patient was
completely spared CNS RT.
Donors and grafts included unrelated mismatched umbilical
double cord transplants (N¼4) and matched related T-cell
depleted bone marrow transplants (N¼2). All six patients
engrafted. One patient succumbed to infectious complica-
tions nearly 2 months post HSCT. The ﬁve other patients are
still alive without marrow or CNS relapse at a median follow-
up of 19.4 months post HSCT (range: 11.1 to 149.5 months) .
While this represents a small patient series, this data pro-
vides evidence for a promising transplant chemotherapy-
only regimen for the transplantation of pediatric patients
with acute leukemia and CNS disease who are unable to
receive TBI, and will be the focus of a larger prospective
study.246
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2 Christian Medical College, Vellore, IndiaAcute GVHD (aGVHD) remains a major challenge in alloge-
neic stem cell transplantation and is associated with signif-
icant morbidity. Though it is associated with a graft versus
leukemia effect in SCT for malignant disorders, it has no
beneﬁt in SCT for non-malignant disorders such as thalas-
semia major.
This is a retrospective analysis of 321 patients who under-
went allogeneic SCT for Thalassemia Major at our centre
between Jan 1991 and Dec 2011. This included 205 males and
116 females with a median age of 7 years (range: 2 - 24).
Patients who expired prior to 2 weeks or had primary graft
rejection were excluded from this analysis. 6.9% of patients
were in Lucarelli Class I, 36.4% in Class II, and 56.7% in Class
III. Donors included matched sibling (n ¼ 299) or other
family donors (n ¼ 22). Conditioning regimen was predom-
inantly Busulfan based (n ¼ 274) while 47 patients received
treosulfan based conditioning. Graft source was mainly bone
marrow (n ¼ 286) while GVHD prophylaxis mainly was
Cyclosporine with short course methotrexate (n ¼ 301).
Acute GVHD (Grade I e IV) occurred in 125 patients (38.9%),
grade II-IV in 28% and grade IV in 5.3%. Donor age (p¼ 0.062),
type of conditioning regimen (p ¼ 0.07), number of doses of
methotrexate administered (p ¼ 0.05), presence of veno-
occlusive disease (VOD) [p ¼ 0.016] and time to neutrophil
engraftment (p ¼ 0.027) were found to be signiﬁcant risk
factors for acute GVHD on a univariate analysis but only VOD
(p ¼ 0.017) and donor age (p ¼ 0.044) remained signiﬁcant
on multivariate analysis. Resolution of GVHD was seen in
90.4% while 9.6% died either due to GVHD or infection. The
3 year overall survival was 80%  2.3% in patients with
GVHD compared to 81.1%  2.9% in patients without GVHD
(p ¼ 0.422).
Acute GVHD is seen in 39% of patients undergoing SCT for
thalassemia major but it does not have a signiﬁcant impact
on overall survival.247
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Background: Hemorrhagic cystitis (HC) is a fairly common
and potentially severe complication observed after hemato-
poietic Stem cell transplantation (HSCT) which may result in
morbidity and extended hospitalization. Its incidence in pe-
diatric patients is unknown.
Methods: We performed a retrospective study on 900 pe-
diatric patients who received HSCT after myeloablative or
reduced intensity conditioning during 1992 e 2011 in our
center. In all, sixty patients (43 male &17 female) developed
HC: early in 35 patients and late in 25 patients. Median age of
patients was 9.19years (range: 2-15). Major thaassemia (45%)
and ALL (18.30%) were most common cause of trans-
plantation. Patients received transplant frommatched donor
(n¼45), 2 locus mismatched (n¼8) and HLA-haploidentical
(n¼7). The source of stem cell were peripheral blood (n¼40),
bone marrow (n¼15) and cord blood (n¼5). Majority of pa-
tient (83.3%) received BU/CY conditioning regiment.
Results: The prevalence of HC was 6.7% in our patients who
all of them had received allogenic HSCT. 4 patients had
pervious history of HC. Acute graft versus host disease
(GvHD) occurred in 46(76.7%) patients. There was no sig-
niﬁcant correlation between the grade of acute GvHD and
